Cargando…

Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells

Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. In the metastatic setting, the majority of patients respond to initial therapies but eventually develop resistance and progress. In this study, we test the hypothesis that priming with epigenetic therapy sensit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Anup, Vatapalli, Rajita, Abdelfatah, Eihab, Wyatt McMahon, K., Kerner, Zachary, A. Guzzetta, Angela, Singh, Jasvinder, Zahnow, Cynthia, B. Baylin, Stephen, Yerram, Sashidhar, Hu, Yue, Azad, Nilofer, Ahuja, Nita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405959/ https://www.ncbi.nlm.nih.gov/pubmed/28445481 http://dx.doi.org/10.1371/journal.pone.0176139

Ejemplares similares

Correction: Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
por: Sharma, Anup, et al.
Publicado: (2020)

Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells
por: Siebenkäs, Cornelia, et al.
Publicado: (2017)

Correction: Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells
por: Siebenkäs, Cornelia, et al.
Publicado: (2020)

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
por: Li, Huili, et al.
Publicado: (2014)

A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing
por: Patel, Kalpesh, et al.
Publicado: (2012)

DNA-intercalators Causing Rapid Re-expression of Methylated and Silenced Genes in Cancer Cells
por: Hossain, M. Zulfiquer, et al.
Publicado: (2013)

Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis
por: Alvarez, Hector, et al.
Publicado: (2011)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Organoids Increase the Predictive Value of in vitro Cancer Chemoprevention Studies for in vivo Outcome
por: Njoroge, Rose N., et al.
Publicado: (2019)

Correction: Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis
por: Alvarez, Hector, et al.
Publicado: (2011)

Hyperlipidemia May Synergize with Hypomethylation in Establishing Trained Immunity and Promoting Inflammation in NASH and NAFLD
por: Drummer, Charles I. V., et al.
Publicado: (2021)

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan
por: Maitra, Radhashree, et al.
Publicado: (2014)

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
por: Yarchoan, Mark, et al.
Publicado: (2017)

Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair
por: Shao, Jinjin, et al.
Publicado: (2016)

EGCG synergizes the therapeutic effect of irinotecan through enhanced DNA damage in human colorectal cancer cells
por: Wu, Wenbing, et al.
Publicado: (2021)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Synergism and Mutualism in Non-Enzymatic RNA Polymerization
por: Kaddour, Hussein, et al.
Publicado: (2014)

Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma
por: Fu, Tao, et al.
Publicado: (2016)

Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients
por: Fu, Tao, et al.
Publicado: (2016)

Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood
por: Eissa, Maryam A. L., et al.
Publicado: (2019)

Methylation of the Claudin 1 Promoter Is Associated with Loss of Expression in Estrogen Receptor Positive Breast Cancer
por: Di Cello, Francescopaolo, et al.
Publicado: (2013)

Dose-Dependent Activation of Putative Oncogene SBSN by BORIS
por: Gaykalova, Daria, et al.
Publicado: (2012)

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study
por: Azad, Nilofer S., et al.
Publicado: (2017)

Irinotecan-Induced Dysarthria
por: Dressel, Albertine J., et al.
Publicado: (2012)

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
por: Yue, Bei, et al.
Publicado: (2021)

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
por: Mahdy, Marwa S., et al.
Publicado: (2023)

Predicting asthma control deterioration in children
por: Luo, Gang, et al.
Publicado: (2015)

Pharmacological interactions: Synergism, or not synergism, that is the question
por: Calzetta, Luigino, et al.
Publicado: (2021)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
por: Jang, Hyun Joo, et al.
Publicado: (2016)

A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer
por: Baretti, Marina, et al.
Publicado: (2023)

P1278: ACTIVATION OF THE NECROPTOSIS PATHWAY PLAYS A ROLE IN SYNERGISM WITH COMBINATION OF THE IAP ANTAGONIST, TOLINAPANT AND HYPOMETHYLATING AGENTS (HMA) IN IN VITRO MODELS OF T-CELL LYMPHOMA (TCL).
por: Manavalan, J. S., et al.
Publicado: (2022)

Effects of methimazole on the elimination of irinotecan
por: van der Bol, Jessica M., et al.
Publicado: (2010)

Malignant Granular Cell Tumor of the Bile Duct
por: Quinn, Patrick L., et al.
Publicado: (2019)

A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
por: Heumann, Thatcher R., et al.
Publicado: (2022)

IRX1 hypomethylation in osteosarcoma metastasis
por: Lu, Jinchang, et al.
Publicado: (2015)

Consistent DNA Hypomethylations in Prostate Cancer
por: Araúzo-Bravo, Marcos J., et al.
Publicado: (2022)

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
por: Yang, Liuting, et al.
Publicado: (2018)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Correction: A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
por: Viúdez, Antonio, et al.
Publicado: (2017)

Comparison of Hypomethylator Monotherapy with Hypomethylator plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis
por: Ji, Jiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nnlrb65lju4ipjp52dddpjpg98